The Official Journal of The Oxygen Society

A Constituent Member of the International Society for Free Radical Research

XIth Meeting of the Society for Free Radical Research International

July 16 – 20, 2002
René Descartes University, Paris, France

Programme and Abstracts
XIth Meeting of the Society for Free Radical Research International

Role of free radicals, oxidants and antioxidants, in molecular and cell biology and life processes. New development and techniques

July 16 – 20, 2002
René Descartes University, Paris, France
Programme and Abstracts
URIC ACID DECREASE AND MALONEDIALDEHYDE CONTENT INDICATE OXIDATIVE STRESS IN THE COURSE OF CHEMOTHERAPY TREATMENT OF LEUKEMIA PATIENTS

Gerova D., Ivanova D., Gerov V., Yankova T., Gercheva L.
University of Medicine, 55 Marin Drinov Street, 9002 Varna, Bulgaria

Plasma levels of antioxidants (uric acid), lipid peroxidation products (malondialdehyde, MDA), and serum iron content were studied as markers of impaired antioxidant status in the course of cytostatic therapy of patients with acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL). Patients with complete remission of AML and ALL appeared to have a significant decrease in plasma uric acid levels, indicating the consumption of uric acid as plasma antioxidant during the chemotherapy-induced oxidative stress. From normal before the treatment the uric acid values decreased to 60% of the normal values at the 4th day of the therapy. At the end of the treatment with cytostatics when leukocytes were lower than 1.10^9/l, the uric acid values stayed below or within the lower limits of the normal range. At the early stage of the disease patients with AML and ALL having high number of blast cells in the blood (over 30.10^9/l) exhibited extremely high values of plasma uric acid content due to the high rate of tumor cell death (900 umol/l plasma uric acid content measured before therapy), masking the decrease during the cytostatic therapy as found for the rest of the AML and ALL patients with uric acid content below the norm at the end of their therapy. A correlation between uric acid consumption and an increase in the lipid peroxidation product MDA, consequence of the oxidative stress, was found for patients with complete remission of AML and ALL and AML and ALL patients with leukocyte levels lower than 1.10^9/l but not for AML and ALL patients with leukocyte levels higher than 30.10^9/l.

THE EFFECT OF TRIBOMECHANICALLY ACTIVATED ZEOLITE (TMZ) ON TOTAL ANTIOXIDANT STATUS OF HEALTHY INDIVIDUALS AND PATIENTS WITH MALIGNANT DISEASE

Dr Slavo Ivkovic, dr Damir Zabec
Meganin International, A-9585 Villach-Godersdorf, Fenkensteiner strasse 5, Austria, tel.: +43(4257)29044, E-mail: damir.zabec@zg.tel.hr. Abstract for session: IV.

Subject of study: Anticancer therapeutic protocols based on specific combination of various antioxidants are accepted. Here we present a new potential antioxidant: tribomechanically activated zeolite TMZ as a product of nanotechnology. TMZ significantly increases total antioxidant status (TAS) and lower free radicals in blood, measured by Free Radicals Analysis System (FRAS). We have performed both tests on patients with malignant disease as well as healthy individuals. TMZ is gained in the process called tribomechanical micronization and activation (nanotechnology). Patients, materials and methods: Total antioxidant status. By measuring Total Antioxidant Status we followed overall activity of three antioxidant enzymes: Superoxid Dismutase (SOD), Glutation Peroxidase (GPx) and Glutation Reductase (GR). We used test system from Randox Laboratories Ltd., Crumlin, United Kingdom. Antioxidants in added sample cause inhibition of the radical (cation ABTS") to a degree that is proportional to their concentration. Test has been performed on 45 individuals; 22 healthy (10 male, 12 female), 18 patients with malignant disease (7 male, 11 female), all in the age of 40–70. 5 individuals were in the control group. FRAS is a system which is able to dose all types of hydroperoxide present in a biological sample via a simple, rapid, reliable and repeatable method using a mere drop of blood. We had 22 female patients and 24 male patients with malignant disease.

Summary: Our results indicate that tribomechanically activated zeolite, clinoptilolite, is potentially a new antioxidant which seems to have bigger capacity than already known antioxidants. We have noticed that patients with malignant disease, who were taking TMZ, have improved their general health condition. TMZ significantly increases TAS values. Conclusion: TMZ can be used as an adjuvants or roborans in any standard therapy of malignant disease, with the aim to improve the general health condition of patients and help them recover much easier and in a shorter period of time.